Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Ms Lina Gurskaite
lina.gurskaite@ecraid.eu


Ms Chanelle Wigger
chanelle.wigger@ecraid.eu


Ms Jeri Nijland
jeri.nijland@ecraid.eu


Dr Alike van der Velden
a.w.vandervelden@umcutrecht.nl


More information about this study, what is involved and how to take part can be found on the study website.

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Clinical trial for the treatment of COVID-19 and COVID-like illness in primary care
Back

Clinical trial for the treatment of COVID-19 and COVID-like illness in primary care

Recruiting

Open to: All Genders

Age: Mixed

Bicester Banbury Faringdon Kidlington Oxford Reading Oxford Honiton Bovey Tracey Oxford Schilde Kontich Edegem Gössenheim Viladecans, Barcelona L'Hospitalet de Llobregat, Barcelona Sant Vicenç dels Horts, Barcelona Tallaght, Dublin 24

Medical Conditions

Reducing illness duration, complications, and possibly transmission of COVID-19 (SARS-CoV-2 infection) and other respiratory pathogens

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Most people with COVID-19 and COVID-like illness do not become seriously ill. Some people, however, do go on to have more serious symptoms and may even need to be admitted to hospital. The aim of this study is to investigate the effectiveness and safety of medicinal products to treat COVID-19 and COVID-like illness in adult patients across Europe. This study will investigate whether the medicinal products help patients to recover patients faster, reduce the severity of the symptoms, reduce complications that require treatment in hospital, and prevent spread to family members/housemates.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

03 Oct 2024 31 Mar 2026

Participants will be randomly allocated to receive either usual care alone or an investigational product, a placebo or a comparator product in addition to usual care.
Participants allocated to the usual care group will receive usual clinical care. Participants allocated to usual care + nitric oxide nasal spray will receive nitric oxide nasal spray (NONS) administered intranasally (into the nose) in addition to usual care, six times per day [two sprays per nostril, equivalent to 0.45 ml volume total per dose (four sprays)], for 7 days.
Participants allocated to usual care + saline nasal spray will receive a saltwater solution administered intranasally in addition to usual care, six times per day [two sprays per nostril, equivalent to 0.45 ml volume total per dose (four sprays)], for 7 days. Participants allocated to the usual care + LTX-109 will receive LTX-109 0.5% weight/weight administered intranasally, three times per day [1 spray per nostril, equivalent to 280uL volume total per dose (2 sprays)] for 3days.
Participants allocated to the usual care + LTX-109-placebo will receive LTX-109 0.0% weight/weight administered intranasally, three times per day [1 spray per nostril, equivalent to 280uL volume total per dose (2 sprays)] for 3days.
The duration of the study for each participant is 3 months. Participants will be monitored daily for their acute symptoms for 28 days with a diary. They will receive a phone call between 28 days and 35 days in case data capture is not complete. Longer-term follow-up will be at 3 months by a phone call or electronic questionnaire. A combined throat/nose swab will be taken at the start of the study and on day 4 for NONS and Saline, and at the start of the study and on days 1, 3 and 5 for LTX-109 and LTX-109-placebo.


Patients aged 18 years or over and experiencing symptoms of a COVID-19 or COVID-like illness, presenting to primary care with COVID-19 and COVID-like-illness in Belgium, France, Germany, Ireland, Poland, Spain and the UK

You can take part if:



You may not be able to take part if:


Current key exclusion criteria as of 13/01/2026:A potential participant who meets any of the following criteria will be excluded from participation in ECRAID-Prime (there can be additional intervention-specific exclusion criteria).1. Requiring admission to the hospital on the day of screening, or inclusion2. Known allergies or hypersensitivities to any of the components used in the formulation of the investigational product, placebo or the comparator product3. Any disease, condition, or disorder that precludes participation in the trial, in the opinion of the person checking eligibility and taking consent4. Any planned major surgery in the next 28 days5. Currently participating in a trial of an investigational product6. Any personnel involved in the study

Previous key exclusion criteria:A potential participant who meets any of the following criteria will be excluded from participation in ECRAID-Prime (there can be additional intervention-specific exclusion criteria). 1. Requiring admission to the hospital on the day of screening, or inclusion2. Known allergies or hypersensitivities to any of the components used in the formulation of the investigational product, or the control product3. Any disease, condition, or disorder that precludes participation in the trial, in the opinion of the person checking eligibility and taking consent4. Any planned major surgery in the next 28 days5. Currently participating in a trial of an investigational product


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Bicester Health Centre
    The Health Centre Coker Close
    Bicester
    OX26 6AT
  • Banbury Cross Health Centre
    South Bar House 6 Oxford Road
    Banbury
    OX16 9AD
  • The White Horse Medical Practice
    The Faringdon Medical Centre Volunteer Way
    Faringdon
    SN7 7YU
  • Gosford Hill Medical Centre
    167 Oxford Road
    Kidlington
    OX5 2NS
  • Hedena Health
    207 London Road Headington
    Oxford
    OX3 9JA
  • Melrose Surgery
    73 London Road
    Reading
    RG1 5BS
  • Nuffield Department of Primary Care Health Sciences, University of Oxford
    Gibson Building 1st floor Radcliffe Observatory Quarter Woodstock Road
    Oxford
    OX2 6GG
  • Honiton Surgery
    Marlpits Lane
    Honiton
    EX14 2NY
  • Bovey Tracey and Chudleigh Medical Practice
    Riverside Surgery, Le Molay, Littry Way
    Bovey Tracey
    TQ13 9QP
  • St. Bartholemews Medical Centre
    Manzil Way
    Oxford
    OX4 1XB
  • Artsenpraktijk Waarloos
    Grote Steenweg 47
    Kontich
    2550
  • Medisch Huis Ter Linden
    Strijdersstraat 20
    Edegem
    2650
  • Hausärztliche Gemeinschaftspraxis Jung/Marold/Beetz
    Hauptstraße 12
    Gössenheim
    97780
  • CAP Mas Font
    Passeig de la Marina, 2
    Viladecans, Barcelona
    08840
  • CAP Alhambra
    C/ de l'Alhambra, 20
    L'Hospitalet de Llobregat, Barcelona
    08902
  • CAP Vila Vella
    Carretera de Sant Boi, 0
    Sant Vicenç dels Horts, Barcelona
    08620
  • GPs at Tallaght Cross
    3rd Floor, Russell Centre, Tallaght Cross West
    Tallaght, Dublin 24
    D24DH74

The overall benefits for participants in the intervention group are related to the prevention or treatment effects of the study drug on their COVID-19 or COVID-like illness. Taking part in the study can have possible disadvantages. Participants may experience side effects from the medicinal product. There may be a brief period of discomfort from (self-)taking the combined throat/nose swabs. Taking part in the study will take up some of the time of the participant.

Ms Lina Gurskaite
lina.gurskaite@ecraid.eu


Dr Alike van der Velden
a.w.vandervelden@umcutrecht.nl


Ms Chanelle Wigger
chanelle.wigger@ecraid.eu


Ms Jeri Nijland
jeri.nijland@ecraid.eu



More information about this study, what is involved and how to take part can be found on the study website.


The study is sponsored by University Medical Center Utrecht and funded by European Union.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN55471843
Last updated 13 January 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top